Nicholas Yacoubian

Full contact info


Outdoor activities

Dallas Cowboys’ football



Sagimet Biosciences – $112.5 Million Follow-On Offering

January 30, 2024

Cooley advised the underwriters in Sagimet Biosciences’ $112.5 million follow-on offering. Goldman Sachs, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering. Sagimet Biosciences’ is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid palmitate. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team.

Related contacts

John McKenna
Partner, Palo Alto
Natalie Karam
Partner, Palo Alto
Denny Won
Partner, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica
David D. Kim
Associate, San Francisco
Nicholas Yacoubian
Associate, Palo Alto
Victoria Comesañas
Associate, Palo Alto

Related Practices & Industries

Admissions & credentials